<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976518</url>
  </required_header>
  <id_info>
    <org_study_id>GOIRC-02-2018</org_study_id>
    <nct_id>NCT03976518</nct_id>
  </id_info>
  <brief_title>Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)</brief_title>
  <acronym>CHANCE</acronym>
  <official_title>Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Rare Histological Subtypes (CHANCE Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Toscano Tumori</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yghea, CRO Division of Bioikos Ambiente srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AOU S. Orsola Malpighi - Clinical Trial Office</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silvano Chiapparoli Logistica SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Oncologico Italiano di Ricerca Clinica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to explore the antitumor activity and the safety profile of atezolizumab
      in pretreated advanced NSCLC patients with rare histological subtypes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm, open label clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the start of treatment (baseline) to the progression of disease (PD) or trial discontinuation whichever occurs first, assessed up to 24 months.</time_frame>
    <description>Proportion of patients presenting Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) based on the Investigator's assessment according to standard RECIST criteria v.1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Safety based on Adverse Events Frequency and Safety</measure>
    <time_frame>From the treatment start to 90 days after the administration of the last treatment dose. The outcome is assessed up to a maximum of 27 months.</time_frame>
    <description>Frequency and Severity of Adverse Events, the latter measured by each Investigator according to NCI Common Terminology Criteria for Adverse Events, version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the start of treatment (baseline) to the progression or stability of disease assessed up to 24 months.</time_frame>
    <description>Proportion of patients presenting Complete Response (CR) or Partial Response (PR) based on Investigator's assessment according to standard RECIST criteria v.1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of enrollment to the date of death from any cause. The survival follow-up will continue until 6 months after the last subject receives the last dose of atezolizumab</time_frame>
    <description>Time from enrollment until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (Time To Progression)</measure>
    <time_frame>From the date of enrollment to the date of objective tumor progression assessed up to 24 months.</time_frame>
    <description>Time from enrollment until objective tumor progression assessed by the Investigators according to standard RECIST criteria v.1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From the date of enrollment to the date of objective disease progression or death assessed up to 24 months.</time_frame>
    <description>Time from enrollment until objective tumor progression or death from any cause or the last date the patient was known-to be progression free or alive</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From the time of documentation of tumor response to the time of disease progression assessed up to 24 months after baseline</time_frame>
    <description>Time from documentation of tumor response (CR or PR) to tumor progression assessed by the Investigators according to standard RECIST 1.1 criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Response</measure>
    <time_frame>The occurrence of a response will be assessed from baseline up to 24 months</time_frame>
    <description>Time from the baseline to a documented tumor response (CR or PR) assessed by the Investigators according to standard RECIST criteria v.1.1.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor shrinkage in target lesions</measure>
    <time_frame>Up to 36 months from the treatment start</time_frame>
    <description>Tumor shrinkage will be determined based on the change in the sum of the longest diameter of target lesions at each time point</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-L1 marker expression on tumor tissue</measure>
    <time_frame>Up to 48 months from the treatment start</time_frame>
    <description>Archival tumor tissue (FFPE tumor block or 7-10 unstained slides) will be assessed for determination of PD-L1 status on tumor cells by using both SP-142 and SP-263 antibody assays</description>
  </other_outcome>
  <other_outcome>
    <measure>Predictable value of PD-L1 tumor expression on tumor response</measure>
    <time_frame>Up to 48 months from the treatment start</time_frame>
    <description>Statistical analysis will be performed to evaluate the role of PD-L1 expression on tumor cells as predictive biomarker of tumor response</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-L1 marker expression on Tumor Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>Up to 48 months from the treatment start</time_frame>
    <description>Archival tumor tissue (FFPE tumor block or 7-10 unstained slides) will be assessed for determination of PD-L1 status on immune cells by using both SP-142 and SP-263 antibody assays</description>
  </other_outcome>
  <other_outcome>
    <measure>Predictable value of PD-L1 TILs expression on tumor response</measure>
    <time_frame>Up to 48 months from the treatment start</time_frame>
    <description>Statistical analysis will be performed to evaluate the role of PD-L1 expression on immune cells as predictive biomarker of tumor response</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between PD-L1 expression both on tumor cells and on immune cells</measure>
    <time_frame>Up to 48 months from the treatment start</time_frame>
    <description>Correlation analysis will be performed with the aim to evaluate PD-L1 expression on both tumor cells and immune cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Accuracy of antibody assays SP-142 and SP-263</measure>
    <time_frame>Up to 48 months from the treatment start</time_frame>
    <description>It will be evaluated the accuracy of both antibody assays and statistical analysis will be performed to investigate their predictive value of response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ATEZOLIZUMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 [± 3] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).</description>
    <arm_group_label>ATEZOLIZUMAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced, relapsed or metastatic non-small cell lung cancer (NSCLC) - stage
             IIIB/IV according to 7th International Association for the Study of Lung Cancer
             (IASLC) classification

          -  Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) with rare
             histological subtype, according to World Health Organization (WHO) 2015
             classification. Histologic subtype variants to be enrolled into the study include:
             colloid adenocarcinoma (or adenocarcinoma with colloid features); fetal adenocarcinoma
             (or adenocarcinoma with fetal features); large cell carcinoma (LCC); sarcomatoid
             carcinoma (pleomorphic, spindle cell, and/or giant cell carcinoma, carcinosarcoma,
             pulmonary blastoma); salivary gland-type tumors (mucoepidermoid carcinoma, adenoid
             cystic carcinoma, epithelial-myoepithelial carcinoma), other and unclassified
             carcinomas (lymphoepithelioma-like carcinoma, NUT-nuclear protein in testis-carcinoma)

          -  Availability of tumor sample (material obtained from core-biopsy or surgical specimen)
             for central pathology revision is mandatory

          -  Availability of a formalin-fixed, paraffin-embedded (FFPE) tumor block or 7-10
             unstained tumor slides suitable for PD-L1 expression assessment is mandatory. The
             assessment of PD-L1 expression will be performed by using both SP-142 and SP-263
             antibody assays. The collection of tumor sample should be performed before patients
             are enrolled into the study

          -  Male and female and ≥ 18 years of age

          -  Life expectancy ≥ 12 weeks

          -  Progressive disease after or during at least one previous standard chemotherapy line

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1
             (RECIST v1.1); clear radiological evidence of disease progression after previous
             treatment has to be documented

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2

          -  Patients with treated brain metastases with stable lesions for at least 2 weeks either
             off steroids or on a stable dose or decreasing dose of steroids (≤ 10 mg prednisone or
             equivalent daily) will be enrolled. Radiotherapy must have been completed a minimum of
             14 days prior to registration, and patients must have recovered from adverse events
             (AEs) related to radiotherapy to &lt; grade 1 (except alopecia)

          -  For Females: must be postmenopausal for at least 1 year before the screening visit, or
             are surgically sterile or not sexually active. Women of childbearing potential (WOCBP)
             must use 2 effective methods of contraception with a failure rate of less than 1% per
             year, during the entire study treatment period and for a period of 5 months after the
             last dose of study drug, or agree to practice true abstinence, when this is in line
             with the preferred and usual lifestyle of the subject. WOCBP must have a negative
             serum pregnancy test during the screening period

          -  Adequate haematological function defined by white blood cell (WBC) count ≥2,500/mm3
             with absolute neutrophil count (ANC) ≥1,500/mm3, platelet count - Adequate hepatic
             function defined by a total bilirubin ≤ 1.5 x the upper limit of normal (ULN) range
             (except subjects with Gilbert Syndrome, who can have total bilirubin &lt; 3.0 mg/dL),
             serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN
             (≤ 5 if liver function test elevations are due to liver metastases)

          -  Adequate renal function defined by a serum creatinine ≤ 1.5 x ULN or an estimated
             creatinine clearance of ≥ 30 mL/minute for patients with creatinine levels above
             institutional limits (if using the Cockcroft-Gault formula)

          -  Stable medical condition, including the absence of acute exacerbations of chronic
             illnesses, serious infections, or major surgery within 4 weeks before registration,
             and otherwise noted in other inclusion/exclusion criteria

          -  Recovered (i.e., ≤ Grade 1 toxicity) from effects of prior anticancer therapy, except
             alopecia

          -  Ability to comply with protocol requirements

          -  The patient is able to provide written informed consent. Voluntary written consent
             must be given before performance of any study-related procedure not part of standard
             medical care, with the understanding that the patient may withdraw consent at any time
             without prejudice to future medical care.

        Exclusion Criteria:

          -  Prior treatment with Atezolizumab or any other immunotherapy agents (anti-PD-1,
             anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or
             drug specifically targeting T-cell costimulation or immune checkpoint pathways)

          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
             or any component of the atezolizumab formulation

          -  Concurrent anticancer treatment, immune therapy, or cytokine therapy, except for
             erythropoietin

          -  Major surgery for any reason within 4 weeks (or 2 weeks for minor surgery) from
             registration and/or if the subject has not fully recovery from the surgery within 4
             weeks of registration

          -  Subjects receiving immunosuppressive agents such as steroids for any reason should be
             tapered off these drugs before initiation of the trial treatment. Corticosteroid
             therapy with a dose ≤ 10 mg prednisone or equivalent will be allowed. Note:

               1. Subjects receiving bisphosphonates or denosumab are eligible provided treatment
                  was initiated at least 14 days before first dose of trial treatment

               2. Previous or ongoing administration of systemic steroids for the management of an
                  acute allergic phenomenon is acceptable as long as it is anticipated that the
                  administration of steroids will be completed in 14 days, or that the daily dose
                  after 14 days will be ≤10 mg per day of equivalent prednisone

          -  Persisting toxicity related to prior therapy of grade &gt;1 according to National Cancer
             Institute - Common Terminology Criteria Adverse Event (NCI-CTCAE) v. 4.03

          -  Known severe hypersensitivity reactions to chimeric or monoclonal antibodies, fusion
             proteins (grade ≥3 NCI-CTCAE v. 4.03)

          -  Patients with untreated, symptomatic and/or progressive brain metastases, or with
             carcinomatous meningitis. Subjects with brain metastases are eligible if metastases
             have been treated and there is no clinical evidence of progression for [lowest minimum
             is 2 weeks or more] after treatment is complete and within 28 days prior to the first
             dose of atezolizumab administration. In addition, subjects must be either off
             corticosteroids, or on a stable or decreasing dose of 10 mg daily prednisone (or
             equivalent)

          -  History of autoimmune disease, including, but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis or glomerulonephritis. Subjects with diabetes mellitus
             type I, hypothyroidism only requiring hormone replacement or controlled
             hyperthyroidism, skin disorders (such as vitiligo, psoriasis, or alopecia) not
             requiring systemic treatment, or conditions not expected to recur in the absence of an
             external trigger are permitted to enrol. Subjects with a condition requiring systemic
             treatment with either corticosteroids (&gt; 10 mg daily prednisone equivalent) or other
             immunosuppressive medications within 14 days of registration will be not eligible.
             Subjects requiring hormone replacement with corticosteroids are eligible if the
             steroids are administered only for the purpose of hormonal replacement and at doses ≤
             10 mg or 10 mg equivalent prednisone per day. Topical, ocular, intra-articular,
             intranasal, and inhalational corticosteroids (with minimal systemic absorption) are
             permitted

          -  Any medical condition requiring a systemic corticosteroid treatment at doses &gt;10 mg
             prednisone per day or equivalent or other immunosuppressive therapies

          -  Other concurrent neoplasms

          -  Prior organ transplantation, including allogenic stem-cell transplantation

          -  Any medical condition, within 6 months before receiving the first dose of study drug,
             considered relevant by Investigator. Chronic stable atrial fibrillation on stable
             anticoagulant therapy is allowed. Patients who present particular clinical conditions
             or relevant comorbidity may be enrolled into the study upon discussion with the Study
             Coordinator

          -  Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency
             syndrome (AIDS)

          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or
             chronic infection

          -  Infection requiring intravenous (IV) antibiotic therapy or other serious infection
             within 14 days before the first dose of study drug

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
             pneumonitis on screening chest computed tomography (CT) scan

          -  Active tuberculosis

          -  Pregnancy or breastfeeding

          -  Vaccination within 4 weeks of the first dose of atezolizumab and while on trial is
             prohibited except for administration of inactivated vaccines (for example, inactivated
             flu vaccines)

          -  Unwilling or unable to comply with the protocol or cooperate fully with the
             investigator and site personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Ardizzoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Oncology-Haematology - S.Orsola-Malpighi Hospital - Bologna - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Gelsomino, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept Oncology-Haematology - S.Orsola-Malpighi Hospital - Bologna - Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Ardizzoni, MD</last_name>
    <phone>+390512142206</phone>
    <email>andrea.ardizzoni@aosp.bo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Gelsomino, MD</last_name>
    <phone>+390512142204</phone>
    <email>francesco_gelsomino@aosp.bo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UO Oncologia Polmonare - AOU S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Novello, MD</last_name>
      <email>silvia.novello@unito.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Novello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO di Oncologia Medica - Azienda Ospedaliero-Universitaria S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ardizzoni, MD</last_name>
      <email>andrea.ardizzoni@aosp.bo.it</email>
    </contact>
    <contact_backup>
      <last_name>Michele Tognetto</last_name>
      <email>michele.tognetto@aosp.bo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Ardizzoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica - Azienda Ospedaliera S.Croce e Carle Cuneo - Ospedale Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Colantonio, MD</last_name>
      <email>colantonio.i@ospedale.cuneo.it</email>
    </contact>
    <contact_backup>
      <email>trials@ospedale.cuneo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Ida Colantonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Grossi, MD</last_name>
      <email>francesco.grossi@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Grossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Rijavec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.S. di Oncologia Medica toraco-polmonare - Fondazione IRCCS - Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Chiara Garassino, MD</last_name>
      <phone>+3902 23903813</phone>
    </contact>
    <investigator>
      <last_name>Marina Chiara Garassino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C Pneumologia ad Indirizzo Oncologico -AORN Ospedali dei Colli Monaldi-Cotugno-CTO</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danilo Rocco, MD</last_name>
      <email>clinicaltrialsrocco@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Danilo Rocco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica 2 - IOV Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Pasello, MD</last_name>
      <email>giulia.pasello@ioveneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Raffaella Verrienti</last_name>
      <email>raffaella.verrienti@ioveneto.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica - Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Tiseo, MD</last_name>
      <email>mtiseo@ao.pr.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Camisa</last_name>
      <email>rcamisa@ao.pr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Marcello Tiseo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US di Oncologia Medica - A.O. di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocco Fausto Roila, MD</last_name>
      <email>roila.fausto@libero.it</email>
    </contact>
    <investigator>
      <last_name>Rocco Fausto Roila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Pneumologia - A.O.U Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Chella, MD</last_name>
      <email>anto.kell@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Anronio Chella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. di Oncologia Medica - IFO - Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabiana Cecere, MD</last_name>
      <email>fabianacecere@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabiana Cecere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica - Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Macerelli, MD</last_name>
      <email>marianna.macerelli@asuiud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Marianna Macerelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.nccn.org</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.</citation>
    <PMID>27827313</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.</citation>
    <PMID>23485231</PMID>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.</citation>
    <PMID>26742998</PMID>
  </reference>
  <reference>
    <citation>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995 Oct 7;311(7010):899-909.</citation>
    <PMID>7580546</PMID>
  </reference>
  <reference>
    <citation>Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.</citation>
    <PMID>18506025</PMID>
  </reference>
  <reference>
    <citation>Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.</citation>
    <PMID>17167137</PMID>
  </reference>
  <reference>
    <citation>Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.</citation>
    <PMID>27718847</PMID>
  </reference>
  <reference>
    <citation>Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009 Dec 20;27(36):6251-66. doi: 10.1200/JCO.2009.23.5622. Epub 2009 Nov 16.</citation>
    <PMID>19917871</PMID>
  </reference>
  <reference>
    <citation>Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii56-64.</citation>
    <PMID>22997455</PMID>
  </reference>
  <reference>
    <citation>Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </reference>
  <reference>
    <citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.</citation>
    <PMID>26412456</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.</citation>
    <PMID>26712084</PMID>
  </reference>
  <reference>
    <citation>Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13. Erratum in: Lancet. 2017 Apr 8;389(10077):e5.</citation>
    <PMID>27979383</PMID>
  </reference>
  <reference>
    <citation>Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13. Erratum in: J Clin Oncol. 2018 Mar 20;36(9):931.</citation>
    <PMID>28609226</PMID>
  </reference>
  <reference>
    <citation>Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.</citation>
    <PMID>26970723</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Sun J, Liang XL, Lu JL, Luo YF, Liang ZY. Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. J Thorac Dis. 2017 Jul;9(7):2071-2078. doi: 10.21037/jtd.2017.07.14.</citation>
    <PMID>28840008</PMID>
  </reference>
  <reference>
    <citation>de Kock L, Bah I, Wu Y, Xie M, Priest JR, Foulkes WD. Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung. J Thorac Oncol. 2016 Mar;11(3):e31-3. doi: 10.1016/j.jtho.2015.09.012. Epub 2015 Dec 10.</citation>
    <PMID>26886166</PMID>
  </reference>
  <reference>
    <citation>Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, Graziano P, Paci M, Stefani A, Migaldi M, Sartori G, Pelosi G. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014 Jan;464(1):61-8. doi: 10.1007/s00428-013-1501-6. Epub 2013 Nov 13.</citation>
    <PMID>24221342</PMID>
  </reference>
  <reference>
    <citation>Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi O, Viale G, Rosai J. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010 Apr;18(2):103-20. doi: 10.1177/1066896908330049. Epub 2009 Jan 4. Review.</citation>
    <PMID>19124452</PMID>
  </reference>
  <reference>
    <citation>Roden AC, Greipp PT, Knutson DL, Kloft-Nelson SM, Jenkins SM, Marks RS, Aubry MC, García JJ. Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma. J Thorac Oncol. 2015 Nov;10(11):1570-5. doi: 10.1097/JTO.0000000000000656.</citation>
    <PMID>26309189</PMID>
  </reference>
  <reference>
    <citation>Salem A, Bell D, Sepesi B, Papadimitrakopoulou V, El-Naggar A, Moran CA, Kalhor N. Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature. Virchows Arch. 2017 Jun;470(6):619-626. doi: 10.1007/s00428-017-2104-4. Epub 2017 Mar 25. Review.</citation>
    <PMID>28343305</PMID>
  </reference>
  <reference>
    <citation>Masuya D, Haba R, Huang CL, Yokomise H. Myoepithelial carcinoma of the lung. Eur J Cardiothorac Surg. 2005 Nov;28(5):775-7. Epub 2005 Sep 26. Review.</citation>
    <PMID>16188445</PMID>
  </reference>
  <reference>
    <citation>He J, Shen J, Pan H, Huang J, Liang W, He J. Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Dis. 2015 Dec;7(12):2330-8. doi: 10.3978/j.issn.2072-1439.2015.12.62.</citation>
    <PMID>26793355</PMID>
  </reference>
  <reference>
    <citation>Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Lüer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, London WB, Sallan SE, Bradner JE, French CA. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012 Oct 15;18(20):5773-9. doi: 10.1158/1078-0432.CCR-12-1153. Epub 2012 Aug 15.</citation>
    <PMID>22896655</PMID>
  </reference>
  <reference>
    <citation>Kim C, Rajan A, DeBrito PA, Giaccone G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016 Dec;5(6):720-726. doi: 10.21037/tlcr.2016.11.06.</citation>
    <PMID>28149767</PMID>
  </reference>
  <reference>
    <citation>Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer. 2016 Sep;99:162-5. doi: 10.1016/j.lungcan.2016.07.010. Epub 2016 Jul 15.</citation>
    <PMID>27565934</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.</citation>
    <PMID>19934295</PMID>
  </reference>
  <reference>
    <citation>Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15;19(14):3936-43. doi: 10.1158/1078-0432.CCR-13-0895. Epub 2013 Jun 6.</citation>
    <PMID>23743568</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC Rare Histological Subtypes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

